Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy. Methods: We reviewed 63 CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy. Among these patients, 30 were treated with ETV + ADV and 33 were treated with ETV + TDF for 12 months. Results: The only baseline characteristic that differed significantly between the two groups was the ETV resistance profile. The rate of a virologic response [serum hepatitis B virus (HBV) DNA level of <20 IU/mL] was significant higher for ETV+TDF than for ETV+ADV over 12 months (57.6% vs. 23.3%, P=0.006, at 6 months; 84.8% vs. 26.7%, P<0.001, at 12 months). The probability of a virologic response was significantly increased in ETV+TDF (P<0.001, OR=54.78, 95% CI=7.15–419.54) and decreased in patients with higher baseline viral loads (P=0.001, OR=0.18, 95% CI=0.07–0.50) in multivariate analysis. No serious adverse event occurred during the study period. Conclusions: In patients with CHB who showed a suboptimal response to LAM and ADV combination therapy, ETV+TDF was superior to ETV+ADV in achieving a virologic response regardless of the HBV resistance profile. Further large-scale and long-term follow-up prospective studies are needed to explain these results. (Clin Mol Hepatol 2015;21:242-248)
Abstract
Background/Aims: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy. Methods: We reviewed 63 CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy. Among these patients, 30 were treated with ETV + ADV and 33 were treated with ETV + TDF for 12 months. Results: The only baseline characteristic that differed significantly between the two groups was the ETV resistance profile. The rate of a virologic response [serum hepatitis B virus (HBV) DNA level of <20 IU/mL] was significant higher for ETV+TDF than for ETV+ADV over 12 months (57.6% vs. 23.3%, P=0.006, at 6 months; 84.8% vs. 26.7%, P<0.001, at 12 months). The probability of a virologic response was significantly increased in ETV+TDF (P<0.001, OR=54.78, 95% CI=7.15–419.54) and decreased in patients with higher baseline viral loads (P=0.001, OR=0.18, 95% CI=0.07–0.50) in multivariate analysis. No serious adverse event occurred during the study period. Conclusions: In patients with CHB who showed a suboptimal response to LAM and ADV combination therapy, ETV+TDF was superior to ETV+ADV in achieving a virologic response regardless of the HBV resistance profile. Further large-scale and long-term follow-up prospective studies are needed to explain these results. (Clin Mol Hepatol 2015;21:242-248)
참고문헌 (26)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines : management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States : 2008 update", Clin Gastroenterol Hepatol, 6, pp.1315~1341 (2008)
- Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- Lok AS, "Chronic hepatitis B:update of recommendations", Hepatology, 39, pp.857~861 (2004)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States", Clin Gastroenterol Hepatol, 2, pp.87~106 (2004)
- de Franchis R, "EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version)", J Hepatol, 39(1), pp.S3~S25 (2003)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Fung J, "Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population", Antivir Ther, 12, pp.41~46 (2007)
- Lampertico P, "Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B : From guidelines to field practice", J Hepatol, 50, pp.644~647 (2009)
- Santantonio T, "Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B", Antivir Ther, 14, pp.557~565 (2009)
- Lim YS, "Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside", nucleotide analogues, 2012, pp.17, 53~60
- Petersen J, "Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients : an international multicenter cohort study", J Hepatol, 56, pp.520~526 (2012)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Chang TT, "A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients", Gastroenterology, 129, pp.1198~1209 (2005)
- Sherman M, "Entecavir therapy for lamivudine-refractory chronic hepatitis B:improved virologic, biochemical, and serology outcomes through 96weeks", Hepatology, 48, pp.99~108 (2008)
- Lim YS, "Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis b who show suboptimal response to lamivudine plus adefovir", Antimicrob Agents Chemother, 56, pp.2941~2917 (2012)
- Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
- Lee YB, "Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis b patients with multidrug-resistant strains", Antimicrob Agents Chemother, 58, pp.6710~6716 (2014)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Gracey DM, "Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection", Antivir Ther, 18, pp.945~948 (2013)
- Kim YJ, "Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures", World J Gastroenterol, 18, pp.6996~7002 (2012)